Updated: 5 days ago
Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
Patients researching malignant tumors may encounter personalized dendritic cell (DC) vaccine therapy as an immunotherapy approach for existing cancers. In China, this therapy is currently available through a special-access pathway in the Hainan Boao Lecheng International Medical Tourism Pilot Zone. This guide explains what the treatment is, who may be considered, its estimated cost, and what international patients should know before pursuing it.
Key Takeaways |
|
What Is Personalized DC Vaccine Therapy for Malignant Tumors?
Personalized DC vaccine therapy is a cancer immunotherapy that uses the patient's own tumor antigens to help activate an immune response against cancer-associated targets.
Dendritic cells play a role in presenting antigens to the immune system. In this personalized approach, the treatment is designed around the patient's tumor characteristics and aims to "educate and activate" the immune system rather than directly target and destroy tumors.
The therapy can be used as a single treatment or alongside standard cancer therapies, depending on the treating physician's assessment. It is a therapeutic vaccine for patients with existing tumors, not a vaccine intended to prevent cancer.
The available treatment information does not establish that the therapy cures cancer or replaces established treatments. Surgery, radiotherapy, chemotherapy, and other standard approaches remain separate components of cancer care where medically indicated. See our full guide for China cancer vaccine here.
Is Personalized DC Vaccine Therapy Available in China?
Yes. The therapy is included in the second wave of approvals for the Lecheng, Hainan Boao Lecheng Pilot Zone, with a transformative application under special access permissions.
This means access is tied to the designated pilot-zone pathway rather than general nationwide availability. The treatment's regulatory classification is listed as low risk, with registration in the second batch in 2025.
International patients should distinguish this special-access availability from nationwide approval in China. Treatment also remains subject to medical assessment and the requirements of the treating hospital.
Where Is the Treatment Offered?
The treatment is offered at Hainan Haikong Le City Hospital (West China Le City Hospital of Sichuan University) within the Hainan Boao Lecheng Pilot Zone.
Technical support is provided by Beijing Likang Life Technology Co., Ltd.
The treatment modality is a personalized dendritic cell vaccine using the patient's own tumor antigens to activate specific T-cell immunity.
Who May Be Eligible?
Eligibility includes individuals undergoing postoperative supportive care or systemic therapy for the listed solid tumor types.
Whether an individual can receive the therapy depends on several clinical factors, including:
Tumor type and stage
Previous cancer treatments
Overall health status
The patient's current treatment situation
The treating physician's assessment of whether the therapy is appropriate
The therapy is not suitable for everyone. It does not replace surgery, radiotherapy, or chemotherapy, and treatment eligibility cannot be determined from the general criteria alone.
Final eligibility is determined by the treating medical team after a face-to-face consultation and comprehensive assessment of the patient's medical records.
How Much Does It Cost?
The estimated cost is (approximately US$22,300) per injection, using a reference exchange rate of about ¥6.72 per US$1.
The quoted treatment price does not necessarily include consultation, diagnostic testing, hospitalization, translation or coordination services, or travel expenses. International patients should confirm the full scope of the price and any additional costs directly with the hospital.
Confirm final pricing directly with the hospital before making travel arrangements.
Why International Patients May Consider This Option
For some international patients, access to a personalized cancer immunotherapy through China's supervised special-access pathway may provide another option to discuss with oncology specialists.
The potential relevance of the therapy depends on the individual's tumor type, stage, treatment history, and overall medical condition. Its availability through the Lecheng pilot pathway should not be interpreted as proof of efficacy or as evidence that it is superior to established cancer treatments.
Patients considering this approach should discuss potential benefits, risks, alternatives, and how it fits into their existing cancer treatment plan with qualified physicians.
How ChinaCureLink Can Help Patients Access This Treatment
We help international patients explore available treatment options and facilitate communication with appropriate medical specialists. Patients should discuss potential benefits, risks, eligibility, and alternatives directly with qualified physicians. ChinaCureLink does not represent or endorse the treatment technology, manufacturer, or hospital.
Case review: We collect relevant medical history and malignant-tumor management records to help determine whether a case is appropriate for physician review.
Hospital coordination: We help connect patients with the treating team at Hainan Haikong Le City Hospital (West China Le City Hospital of Sichuan University) in China for an initial assessment.
Online consultation before travel: Patients can discuss potential eligibility, the procedure, and expected next steps with the medical team remotely before committing to international travel.
Coordination support: Depending on the case, this can include translation assistance, appointment scheduling, and logistics coordination.
Considering This Treatment in China?
Before planning travel, speak with a qualified specialist to determine whether the treatment is appropriate for your condition and whether you meet the medical eligibility requirements. ChinaCureLink can help international patients arrange a specialist review and explore the treatment pathway in China. Request a Medical Review / Speak With a Specialist
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Is personalized DC vaccine therapy available in China?
Yes. It is available through the Hainan Boao Lecheng Pilot Zone's second-wave special-access pathway at Hainan Haikong Le City Hospital. This pilot-zone access does not mean nationwide approval.
How much does personalized DC vaccine therapy cost in China?
The estimated cost is approximately US$22,300, per injection. Patients should confirm final pricing and what the quoted amount covers with the hospital.
Who may qualify for a personalized DC vaccine for cancer?
Potential candidates include individuals receiving postoperative supportive care or systemic therapy for eligible solid tumors. Eligibility depends on tumor type and stage, previous treatments, overall health, and physician assessment.
Is the DC vaccine a preventive cancer vaccine?
No. It is a therapeutic vaccine intended for patients with existing tumors. It is not a preventive cancer vaccine and does not guarantee a cure or replace standard cancer treatments.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
